We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
- Authors
Michaelson, M Dror; Kaufman, Donald S; Lee, Hang; McGovern, Francis J; Kantoff, Philip W; Fallon, Mary Anne; Finkelstein, Joel S; Smith, Matthew R
- Abstract
Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 9, p1038
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.07.3361